Lancet Infect Dis2023 Sep.
カルバペネム耐性Acinetobacter baumannii-calcoaceticus complex感染症治療におけるsulbactam-durlobactamとcolistinの有効性と安全性:多施設、無作為化、アクティブ制御、第3相、非劣性臨床試験(ATTACK)
Efficacy and safety of sulbactam-durlobactam versus colistin for the treatment of patients with serious infections caused by Acinetobacter baumannii-calcoaceticus complex: a multicentre, randomised, active-controlled, phase 3, non-inferiority clinical trial (ATTACK).
Kaye KS, Shorr AF, Wunderink RG, Du B, Poirier GE, Rana K, Miller A, Lewis D, O'Donnell J, Chen L, Reinhart H, Srinivasan S, Isaacs R, Altarac D